Medication use among patients with Crohn’s disease or ulcerative colitis before and after the initiation of advanced therapy

Theresa Hunter1*, April N. Naegeli1, Chi Nguyen2, Mingyang Shan1, Joseph L. Smith2, Hiangkiat Tan2, Klaus Gottlieb1 and Keith Isenberg3

Abstract

Background: Although various treatments help reduce abdominal pain, real-world pain medication utilization among patients with Crohn’s disease (CD) or ulcerative colitis (UC) receiving advanced therapies is poorly understood. The aim is to understand the utilization of pain medication 12 months before and after the initiation of advanced therapies among patients with newly diagnosed CD or UC.

Methods: This retrospective, observational cohort study used administrative medical and pharmacy claims data of patients with CD or UC from HealthCore Integrated Research Database (HiRD®). The data from patients with use of pain medication over 12 months follow-up (after the initiation date of advanced therapies) were collected and analyzed. Differences in the use of pain medication 12 months before and after the initiation of advanced therapies were assessed using McNemar’s and Wilcoxon signed-rank test.

Results: Prior to initiating advanced therapies, 23.1% of patients with CD (N = 540) received nonsteroidal anti-inflammatory drugs (NSAIDs), 78.1% glucocorticoids, 49.4% opioids, and 29.3% neuromodulators; similarly, 20.9% of patients with UC (N = 373) received NSAIDs, 91.4% glucocorticoids, 40.8% opioids, and 29.5% neuromodulators. After receiving advanced therapies for 12 months, patients reported a reduction in the use of steroids (78.1% vs. 58.9%, P < 0.001 in CD; 91.4% vs. 74.3%, P < 0.001 in UC), opioids (49.4% vs. 41.5%, P = 0.004 in CD; 40.8% vs. 36.5%, P = 0.194 in UC), and NSAIDs (23.1% vs. 15.0%, P < 0.001 in CD; 20.9% vs. 15.8%, P = 0.035 in UC), while the use of neuromodulators significantly increased (29.3% vs. 33.7%, P = 0.007 in CD; 29.5% vs. 35.7%, P = 0.006 in UC).

Conclusions: The use of pain medications such as NSAIDs, glucocorticoids, opioids, and neuromodulators was common among patients with CD or UC. These results highlight that patients with CD or UC continued to receive pain medications even after initiating advanced therapies.

Keywords: Abdominal pain, Advanced therapies, Crohn’s disease, Ulcerative colitis

Background

Inflammatory bowel disease (IBD) is a chronic, progressive inflammatory disorder of the gastrointestinal tract, and includes Crohn’s disease (CD) and ulcerative colitis (UC) as its 2 major forms [1]. The United States (US) has reported the highest age-standardized prevalence rate, accounting for nearly one-fourth of the global IBD cases [2]. The estimated prevalence of IBD ranges from 252 to 439 cases per 100,000 population in US [3], creating sustained demand on health care delivery systems and communities in treating IBD [4].

*Correspondence: hunter_theresa_marie@lilly.com

1 Eli Lilly and Company, 893 S. Delaware Street, Indianapolis, IN 46225, USA
Full list of author information is available at the end of the article
Pain due to inflammation during the early phase of IBD, affects 50–70% of patients [5] and contributes to the poor quality of life (QoL) [6]. Chronic abdominal pain is one of the primary presenting symptoms in patients seeking medical care during initial diagnosis or exacerbation of IBD [7, 8]. Although the therapeutic strategy for IBD aims at reducing chronic abdominal pain, a significant number of patients (20–50%) continue experiencing it even during periods of remission [9, 10]. In addition, extra-intestinal manifestations can also cause pain in patients with IBD [11]. Primary inflammatory manifestations in patients with IBD include inflammation of the skin, eyes, and joints. If secondary effects of disease are also considered, nearly 100% of patients with IBD have an abnormality outside of the gastrointestinal tract lumen [12]. The complex associations among pain, anxiety, depression, and QoL observed in multiple IBD cohort studies have established the critical need for effective individualized management of abdominal pain [13].

Treating pain in patients with IBD can be challenging, as commonly used therapies such as nonsteroidal anti-inflammatory drugs (NSAIDs), opioids, and corticosteroids have been associated with an increased risk of disease exacerbation and other adverse outcomes [14, 15]. However, these medications and advanced therapies [e.g., tumor necrosis factor inhibitors (TNFi), non-TNFi, and Janus kinase inhibitors (JAKi)] provide symptomatic relief and can result in healing of the inflamed intestine in CD or UC conditions [16, 17]. Use of advanced therapies such as TNFi and JAKi have improved the health-related QoL in patients with IBD by decreasing symptomatology associated with hospital admissions and reducing side effects experienced from the use of other conventional therapies [18–20]. Although advanced therapies have been shown to achieve clinical response in patients with CD or UC, their role in reducing the use of other pain medications to alleviate pain symptoms in IBD remains poorly understood.

Though various treatments show promising results in reducing abdominal pain [7], real-world pain medication utilization among patients receiving advanced therapies is not adequately understood [21]. The goal of this study is to better understand the utilization of pain medications 12 months before and after the initiation of advanced therapies among the newly diagnosed patients with CD or UC in commercially insured or Medicare Advantage US populations.

**Methods**

**Study design and data source**

This retrospective, observational cohort study used administrative medical and pharmacy claims data of patients with CD or UC from the HealthCore Integrated Research Database (HIRD). The HIRD represents a broad, clinically, and geographically diverse spectrum of longitudinal claims data from US patients who are insured through Anthem’s commercial or Medicare Advantage health plans in the Northeastern, Southern, Midwestern, and Western regions. As of Q1 2019, the HIRD contained data of over 51 million individuals dating back to January 1, 2006. The HIRD is updated monthly with fully adjudicated paid claims.

The data were used in full compliance with the relevant provisions of the Health Insurance Portability and Accountability Act of 1996 (HIPAA). The study was conducted under the research provisions of Privacy Rule 45 Code of Federal Regulations (CFR) 164.514(E). This study was conducted in accordance with legal and regulatory requirements, scientific purpose, value and rigor, and follow Good Practices for Outcomes Research issued by the International Society for Pharmacoeconomics and Outcomes Research (ISPOR).

**Patient population**

Newly diagnosed adult patients with CD or UC from January 1, 2014 till July 31, 2017 using International Classification of Diseases (ICD), ninth revision, Clinical Modification (CM) (ICD-9-CM: 555.xx for CD; 556.xx for UC) and tenth revision (ICD-10-CM: K50.x for CD; K51.x for UC) codes were included. Other inclusion criteria were ≥ 2 claims for advanced therapies of interest following CD or UC diagnosis between the first diagnosis of CD or UC and the end of the study period, having ≥ 1 year of continuous health plan enrollment prior to the initiation date of advanced therapies (index date), and ≥ 1 year of continuous health plan enrollment after index date.

In patients with CD, the following US Food and Drug Administration (FDA)-approved advanced therapies were included: natalizumab, certolizumab pegol, adalimumab, infliximab, vedolizumab, and ustekinumab. Similarly, in patients with UC, the following FDA-approved advanced therapies were included: adalimumab, infliximab, golimumab, vedolizumab, tofacitinib, and ustekinumab.

Patients with juvenile idiopathic arthritis or those with other/multiple autoimmune conditions such as ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, and systemic lupus erythematosus were excluded. Also, patients with both CD and UC were excluded from the study.

**Study outcomes**

Data on demographic and clinical characteristics, and the use of pain medication over 12 months follow-up (after the index date), were collected and analyzed.
Any chronic, unclassified pain condition (general pain, fibromyalgia, pelvic pain, abdominal pain, muscle pain, or myalgia) was identified during baseline period and classified according to Romanelli et al. [22]. The number and percentage of patients with ≥ 1 medical claim(s) for the above-mentioned conditions were reported.

Pain medications included NSAIDs, glucocorticoid steroids, non-narcotic analgesics, opioids (chronic opioid use ≥ 180 days), and neuromodulators (antidepressants, anticonvulsants, muscle relaxants). The frequency or percentage of patients with ≥ 1 fills and number of fills of each pain medication listed were reported during the baseline period and first year after the index date.

Adherence to advanced therapies was measured by the proportion of days covered (PDC) as defined in literature [23]. The PDC was calculated as the number of days with drug on-hand or number of days exposed to drug divided by the number of days in the specified time interval. Adherence was defined as PDC ≥ 80% [23]. PDC was assessed during 12 months after the initiation of advanced therapies. The change in pain medication fills in both CD and UC cohorts was reported 12 months after the initiation of advanced therapies. The mean time from diagnosis to the initiation of advanced therapies was 7.1 months for the CD cohort and 10.9 months for the UC cohort.

Baseline demographics and clinical characteristics of the patients included are presented in Table 1. The mean ± SD age of patients with CD and UC were 36.8 ± 14.6 years and 39.9 ± 15.2 years, respectively. Most incident cases with CD (50.9%) and UC (43.2%) belonged to the age category of 18–34 years. A total of 50% of patients in the CD cohort were females and 44% were females in the UC cohort. Majority of the patients with CD (35.6%) or UC (32.7%) were from the Southern region of the US. The mean time from diagnosis to the initiation of advanced therapies was 7.1 months for the CD cohort and 10.9 months for the UC cohort.

Pain medication use
Before the initiation of advanced therapies, 23.1% of patients with CD were prescribed NSAIDs, 78.1% glucocorticoids, 49.4% opioids, and 29.3% neuromodulators; similarly, 20.9% of patients with UC received NSAIDs, 91.4% glucocorticoids, 40.8% opioids, and 29.5% neuromodulators (Figs. 3, 4).

However, 12 months after the initiation of advanced therapies, there was a significant reduction in the use of glucocorticoids (78.1% vs. 58.9%, *P* < 0.001 in CD; 91.4% vs. 74.3%, *P* < 0.001 in UC), opioids (49.4% vs. 41.5%, *P* = 0.004 in CD; 40.8% vs. 36.5%, *P* = 0.194 in UC), and prescription-based NSAIDs (23.1% vs. 15.0%, *P* < 0.001 in CD; 20.9% vs. 15.8%, *P* = 0.035 in UC), while the use of neuromodulators significantly increased (29.3% vs. 33.7%, *P* = 0.007 in CD; 29.5% vs. 35.7%, *P* = 0.006 in UC) (Figs. 3, 4).

Number of pain medication fills
In the CD cohort, the generalized estimating equation models showed that there was no significant change in pain medication fills/administrations among patients who adhered to advanced therapies (exponentiated estimate [EE]: 0.89; *P* = 0.0638). On the other hand, non-adherent patients had 17% more pain medication fills/administrations (EE: 1.17; *P* = 0.0375; Table 2) when compared to the initiation of advanced therapies before 12 months.

The number of pain medication fills were significantly associated with presence of baseline conditions such as back/cervical pain (EE: 1.24, 95% confidence interval [CI] 1.01–1.53, *P* = 0.0432), neuropathies/neuralgias (EE: 1.28, 95% CI 1.02–1.62, *P* = 0.0358), middle age group (35 to 44 years; EE: 1.32, 95% CI 1.09–1.59, *P* = 0.0043), and female patients (EE: 1.27, 95% CI 1.09–1.47, *P* = 0.0019).

In the UC cohort, it was observed that after controlling the baseline factors, there was no significant change in pain medication fills/administrations among adherent (EE: 0.95; *P* = 0.3668) and non-adherent patients.
Patients with ≥1 day of medical and pharmacy enrollment during intake period; N=20,079,885

≥2 claims on different dates for CD during the study period; N=44,816

Age ≥18 on index date; N=32,071

Patients with ≥365 days of continuous health plan enrollment prior to index date (baseline period); N=16,618

Newly diagnosed cases; N=4,555

≥2 claims for an indicated advanced therapies after index date; N=720

≥183 days of continuous enrollment prior and ≥183 days of continuous enrollment after drug initiation date; N=631

Patients with ≥365 days of continuous enrollment prior and ≥365 days of continuous enrollment after drug initiation date; N=540

Exclusion

Patients without ≥ 2 claims on different dates for UC during the study period N= 2,003,569

Patients with:
- ≥2 claims for RA, PsA, SLE, AS, UC: 9950
- juvenile idiopathic arthritis: 39
- metastatic cancer: 732
- <18 years on index date: 2024

Patients with index autoimmune disease or any DMARD treatment prior to index date: 12,065

Fig. 1 Study disposition and inclusion of patients in CD cohort. AS ankylosing spondylitis, CD Crohn’s disease, DMARD disease-modifying antirheumatic drug, PsA psoriatic arthritis, RA rheumatoid arthritis, SLE systemic lupus erythematosus, UC ulcerative colitis

(EE: 1.15; P = 0.0769; Table 3) after initiating advanced therapies.

The age of patients (35 to 44 years; EE: 1.31, 95% CI 1.04–1.65, P = 0.0223; 45 to 54 years; EE: 1.31, 95% CI 1.02–1.67, P = 0.0312 as compared with a younger group of 18 to 34 years) and presence of other baseline conditions such as hypertension (EE: 1.40, 95% CI 1.13–1.73, P = 0.0022) and mental illness/substance use disorders (EE: 1.64, 95% CI 1.38–1.94, P < 0.0001) were associated with higher number of pain medication fills.

Discussion

This study provides real-world information on the treatment patterns for the use of medication to reduce pain in patients with CD or UC during the 12-month period before and after the use of advanced therapies. Our findings suggested that patient prescriptions filled for pain medications decreased across both disease cohorts after 12 months compared with before 12 months of initiation of advanced therapies. Despite the reduction, the usage of pain medication remained relatively high across both disease cohorts. Prior to the initiation of advanced therapies, steroids were among the most common medications used, followed by opioid pain treatment in both CD and UC cohorts.

Corticosteroids were the preferred choice to treat CD; whereas 5-aminosalicylic acids (5-ASA) followed by corticosteroids were the most common initial treatment for UC [24]. While the effectiveness of corticosteroids, NSAIDs, and opioids in relieving pain is documented [25], they are associated with several serious adverse drug reactions such as exacerbating gut symptoms and bowel dysmotility [26], limiting their long-term use. A significant number of patients use opioids or marijuana for pain control despite the psychological and disease-related risks [27].

A recent study using the Truven MarketScan Commercial Claims and Encounters database has shown that an increasingly larger proportion of patients were treated with advanced therapies from 2007 to 2015 (CD: 21.8–43.8%; UC: 5.1–16.2%) relative to more stable use of immunomodulators or 5-ASA [28] and similar to patterns observed in other studies using claims data [29, 30]. Other studies suggest that patients are much more likely to follow non-biologic treatment pathways compared with advanced therapies treatment pathways for CD (81%
Patients with ≥1 day of medical and pharmacy enrollment during intake period; N=20,079,885

≥2 claims on different dates for UC during the study period; N=48,272

Age ≥18 on index date; N=37,245

Patients with ≥365 days of continuous health plan enrollment prior to index date (baseline period); N=21,654

Newly diagnosed cases; N=7,445

≥2 claims for an indicated advanced therapies after index date; N=516

≥183 days of continuous enrollment prior to and ≥183 days of continuous enrollment after drug initiation date; N=456

Patients with ≥365 days of continuous enrollment prior to and ≥365 days of continuous enrollment after drug initiation date; N=373

Exclusion

Patients without ≥2 claims on different dates for UC during the study period N=2,00,31,613

Patients with:
- ≥2 claims for RA, PA, SLE, AS, CD: 9,147
- juvenile idiopathic arthritis ≤ 15
- metastatic cancer: 860
- ≤18 years on index date: 1,005

Patients with index autoimmune disease or any DMARD treatment prior to index date: 14,209

Fig. 2 Study disposition and inclusion of patients in the UC cohort. AS ankylosing spondylitis, CD Crohn’s disease, DMARD disease-modifying antirheumatic drug, PsA psoriatic arthritis, RA rheumatoid arthritis, SLE systemic lupus erythematosus, UC ulcerative colitis

vs. 19%; P<0.05, t-test) and UC (94% vs. 6%; P<0.05, t-test) [24]. We observed similar trends wherein newly diagnosed patients were more likely to utilize pain medications over advanced therapies.

The current analysis corroborates the patterns observed in previous work where the first advanced therapy was initiated in CD and UC cohorts after the use of corticosteroids and immunomodulators [24]. We observed that the use of steroids and NSAIDs decreased significantly in 12 months after the initiation of advanced therapies, whereas the use of neumodulators increased in both the cohorts. Although the use of these pain medications decreased after the initiation of advanced therapies, their use was still prevalent among patients. We observed that 41.5% of patients with CD and 36.5% of patients with UC received opioids; 58.9% and 74.3% of patients with CD and UC, respectively, were prescribed corticosteroids after initiating advanced therapies. Since opioids have overarching effects on pain regulation regardless of the source of pain, their chronic use has been reported in 30% of patients with IBD, referred for psychiatric evaluation [31]. On the other hand, the frequency of opioid use ranged from 3 to 13% in all the patients presenting to an IBD clinic [32, 33], much lower than the prevalence reported here. Opioids can complicate IBD, as increasing doses of narcotics will cause or aggravate the pain that is being treated and increase the risk of narcotic bowel syndrome characterized by chronic abdominal pain [6]. The increased use of other neuromodulators could be an indication of efforts to decrease the use of opioids. Only 45% of newly diagnosed patients with UC required corticosteroids [34], compared with the current data wherein more than half of the patients with both CD (58.9%) and UC (74.3%) continued their use. The prevalence of steroids use even after the initiation of advanced therapies indicates that the patients were not in corticosteroid-free remission. Although patients continued with other therapies for pain, the pain medication fills significantly decreased in adherent patients 12 months after the initiation of advanced therapies in CD.

Of the approved advanced therapies for CD or UC, TNFi and α4β7 integrin receptor antagonists were commonly used [35, 36]. In our study, most of the patients with CD (95.0%) or UC (89.3%) used TNFi during the 12 months of advanced therapy use in our study (data not shown), confirming prior findings [35, 36]. Irrespective
of the symptoms/disease condition, it has also been reported that these drugs can be highly effective whether administered as monotherapy or in combination with pain medications early in the disease course. In both CD and UC, poor disease control with prior therapies is one reason for the initiation of advanced therapies. Studies cited here and supported by this analysis show that the management of IBD has evolved in the last decade to

Table 1  Baseline demographic and clinical characteristics

|                      | CD | UC |
|----------------------|----|----|
| **Age on index date (years)** |  |    |
| Mean (SD)            | 36.8 (14.6) | 39.9 (15.2) |
| **Age categories, n (%)** |  |    |
| 18–34                | 275 (50.9) | 161 (43.2) |
| 35–44                | 96 (17.8)  | 82 (22.0) |
| 45–54                | 86 (15.9)  | 58 (15.5) |
| 55–64                | 69 (12.8)  | 49 (13.1) |
| ≥65                  | 14 (2.6)   | 23 (6.2)  |
| **Sex, n (%)**       |  |    |
| Female               | 270 (50.0) | 164 (44.0) |
| **Residence region, n (%)** |  |    |
| Northeast            | 88 (16.3)  | 62 (16.6) |
| Midwest              | 160 (29.6) | 104 (27.9) |
| South                | 192 (35.6) | 122 (32.7) |
| West                 | 94 (17.4)  | 84 (22.5) |
| **Plan type, n (%)** |  |    |
| HMO                  | 141 (26.1) | 79 (21.2) |
| PPO                  | 299 (55.4) | 232 (62.2) |
| CDHP                 | 100 (18.5) | 62 (16.6) |
| Other/unknown        | 0 (0)      | 0 (0) |
| **Index diagnosis, n (%)** |  |    |
| 2014                 | 142 (26.3) | 103 (27.6) |
| 2015                 | 175 (32.4) | 114 (30.6) |
| 2016                 | 141 (26.1) | 109 (29.2) |
| 2017                 | 82 (15.2)  | 47 (12.6) |
| **Time from index diagnosis to the initiation date of advanced therapies (months)** |  |    |
| Mean (SD)            | 7.1 (9.1)  | 10.9 (11.1) |
| **Provider specialty on index date, n (%)** |  |    |
| Gastroenterologist   | 166 (30.7) | 128 (34.3) |
| Primary care physician| 35 (6.5)  | 28 (7.5)  |
| Others               | 334 (61.9) | 217 (58.2) |
| **QCI**              |  |    |
| Mean (SD)            | 0.4 (0.8)  | 0.5 (1.0)  |
| **Comorbid conditions, n (%)** |  |    |
| Peripheral vascular disease | 16 (3.0) | 11 (2.9) |
| Chronic pulmonary disease | 61 (11.3) |  |
| Mild liver disease   | 49 (9.1)   |  |
| Diabetes without chronic complication | 24 (4.4) | 32 (8.6) |
| Anemia               | 183 (33.9) | 134 (35.9) |
| Dyslipidemia         | 71 (13.1)  | 79 (21.2) |
| Fibromyalgia         | 14 (2.6)   |  |
| Hypertension         | 105 (19.4) | 88 (23.6) |
| Mental illness       | 201 (37.2) | 118 (31.6) |
| Osteoarthritis       | 35 (6.5)   | 28 (7.5)  |
| Infections           | 291 (53.9) | 207 (55.5) |
| Nicotine dependence/tobacco use disorder | 121 (22.4) | 72 (19.3) |

**CD** Crohn's disease, **CDHP** Consumer Directed Health Plan, **QCI** Quan-Charlson Comorbidity Index, **SD** standard deviation, **UC** ulcerative colitis, **HMO Health Maintenance Organization, PPO** Preferred Provider Organization, ref reference

*Denotes a cell value ≤ 10 that was blinded for privacy reasons

Fig. 3  Use of pain medication for CD: before and after the initiation of advanced therapies. *P-value calculated using McNemar’s test for categorical variables and paired t-test or Wilcoxon signed-rank test for continuous variables

*P<0.05

Fig. 4  Use of pain medication for UC: before and after the initiation of advanced therapies. *P-value calculated using McNemar’s test for categorical variables and paired t-test or Wilcoxon signed-rank test for continuous variables

*P<0.05
Table 2  CD cohort: number of pain medication fills/administrations before and after advanced therapy initiation (GEE model)

|                                                                 | Exponentiated estimate | 95% confidence interval | P value |
|-----------------------------------------------------------------|------------------------|-------------------------|---------|
| **Advanced therapy PDC (ref = 0, before initiation)**            |                        |                         |         |
| PDC 0–0.8 (nonadherence)                                        | 1.17                   | 1.01, 1.35              | 0.0375  |
| PDC ≥ 0.8 (adherence)                                            | 0.89                   | 0.79, 1.01              | 0.0638  |
| Baseline arthritis/joint pain (ref = no)                        | 0.97                   | 0.78, 1.19              | 0.7502  |
| Baseline back/cervical pain (ref = no)                           | 1.24                   | 1.01, 1.53              | 0.0432  |
| Baseline neuropathies/neuralgias (ref = no)                     | 1.28                   | 1.02, 1.62              | 0.0358  |
| Baseline migraines/headaches (ref = no)                         | 1.23                   | 0.93, 1.62              | 0.1507  |
| Baseline unclassified pain (ref = no)                           | 1.05                   | 0.85, 1.29              | 0.6571  |
| **Age (ref = 18–34)**                                           |                        |                         |         |
| 35–44                                                            | 1.32                   | 1.09, 1.59              | 0.0043  |
| 45–54                                                            | 1.23                   | 0.96, 1.56              | 0.0996  |
| 55–64                                                            | 1.00                   | 0.79, 1.27              | 0.9873  |
| ≥ 65                                                             | 0.95                   | 0.52, 1.73              | 0.8610  |
| **Female (ref = male)**                                         | 1.27                   | 1.09, 1.47              | 0.0019  |
| **Residence region (ref = Northeast)**                          |                        |                         |         |
| Midwest                                                          | 1.17                   | 0.93, 1.46              | 0.1832  |
| South                                                            | 1.05                   | 0.85, 1.30              | 0.6693  |
| West                                                             | 1.05                   | 0.81, 1.37              | 0.7087  |
| Other/unknown                                                    | 0.94                   | 0.34, 2.61              | 0.9042  |
| **Plan type (ref = HMO)**                                       |                        |                         |         |
| PPO                                                              | 0.97                   | 0.82, 1.16              | 0.7573  |
| CDHP                                                             | 0.90                   | 0.71, 1.13              | 0.3490  |
| Medicare Advantage or Supplement coverage (ref = no)             | 1.38                   | 0.70, 2.73              | 0.3588  |
| **At initiation year (ref = 2014)**                             |                        |                         |         |
| 2015                                                             | 0.94                   | 0.74, 1.20              | 0.6249  |
| 2016                                                             | 0.89                   | 0.69, 1.15              | 0.3677  |
| 2017                                                             | 0.83                   | 0.64, 1.08              | 0.1619  |
| 2018                                                             | 0.56                   | 0.37, 0.85              | 0.0062  |
| **Duration from index diagnosis to advanced therapy initiation (months)** | 1.01       | 1.00, 1.02              | 0.1467  |
| **QCI (ref = 0)**                                                |                        |                         |         |
| 1                                                                | 1.37                   | 1.10, 1.71              | 0.0045  |
| 2                                                                | 1.11                   | 0.88, 1.39              | 0.3718  |
| 3+                                                               | 0.92                   | 0.52, 1.64              | 0.7848  |
| **Other baseline conditions**                                   |                        |                         |         |
| Anemia (ref = no)                                                | 1.13                   | 0.97, 1.31              | 0.1172  |
| Dyslipidemia (ref = no)                                          | 1.31                   | 1.05, 1.64              | 0.0178  |
| Fibromyalgia (ref = no)                                          | 1.69                   | 1.22, 2.32              | 0.0014  |
| Hypertension (ref = no)                                          | 1.30                   | 1.07, 1.59              | 0.0093  |
| Mental illness/substance use disorders (ref = no)                | 2.03                   | 1.72, 2.39              | <0.0001 |
| Osteoporosis (ref = no)                                          | 1.20                   | 0.47, 3.07              | 0.7060  |
| Infections (ref = no)                                            | 1.16                   | 1.00, 1.35              | 0.0547  |
| Nicotine dependence (ref = no)                                   | 0.87                   | 0.72, 1.05              | 0.1419  |

Model adjusted for baseline pain conditions, age, gender, geographic region, plan type, Medicare Advantage coverage, duration of index diagnosis to advanced therapies initiation, QCI, and other baseline conditions.

CD Crohn's disease, CDHP Consumer Driven Health Products, GEE generalized estimating equations, HMO Health Maintenance Organization, PDC proportion of days covered, PPO Provider Preferred Organization, QCI Quan-Charlson Comorbidity Index, ref reference.
## Table 3
Advanced UC cohort: number of pain medication fills/administrations before and after advanced therapy initiation (GEE model)

|                                | Exponentiated estimate | 95% confidence interval | P value |
|--------------------------------|------------------------|-------------------------|---------|
| **Advanced therapy PDC (ref = 0, before initiation)** |                        |                         |         |
| PDC 0–0.8 (nonadherence)       | 1.15                   | 0.98, 1.35              | 0.0769  |
| PDC ≥ 0.8 (adherence)          | 0.95                   | 0.85, 1.06              | 0.3668  |
| Baseline arthritis/joint pain (ref = no) | 1.22                   | 0.99, 1.50              | 0.0563  |
| Baseline back/cervical pain (ref = no) | 1.02                   | 0.82, 1.27              | 0.8367  |
| Baseline neuropathies/neuralgias (ref = no) | 1.01                   | 0.79, 1.28              | 0.9612  |
| Baseline migraines/headaches (ref = no) | 1.34                   | 1.00, 1.80              | 0.0504  |
| Baseline unclassified pain (ref = no) | 1.23                   | 0.93, 1.61              | 0.1426  |
| **Age (ref = 18–34)**          |                        |                         |         |
| 35–44                          | 1.31                   | 1.04, 1.65              | 0.0223  |
| 45–54                          | 1.31                   | 1.02, 1.67              | 0.0312  |
| 55–64                          | 1.27                   | 0.98, 1.65              | 0.0661  |
| ≥ 65                           | 1.37                   | 0.89, 2.11              | 0.1491  |
| **Female (ref = male)**        |                        |                         |         |
|                                | 1.09                   | 0.93, 1.29              | 0.2851  |
| **Residence Region (ref = Northeast)** |                    |                         |         |
| Midwest                        | 0.97                   | 0.76, 1.25              | 0.8274  |
| South                          | 1.13                   | 0.90, 1.42              | 0.3104  |
| West                           | 1.23                   | 0.95, 1.59              | 0.1216  |
| Other/unknown                  | 1.85                   | 1.36, 2.51              | <0.0001 |
| **Plan type (ref = HMO)**      |                        |                         |         |
| PPO                            | 0.94                   | 0.78, 1.13              | 0.4925  |
| CDHP                           | 0.88                   | 0.68, 1.14              | 0.3353  |
| Medicare Advantage or Supplement coverage (ref = no) | 0.76                   | 0.46, 1.26              | 0.3840  |
| **At initiation year (ref = 2014)** |                    |                         |         |
| 2015                           | 1.08                   | 0.72, 1.61              | 0.7209  |
| 2016                           | 1.05                   | 0.71, 1.57              | 0.7989  |
| 2017                           | 1.03                   | 0.68, 1.55              | 0.8915  |
| 2018                           | 0.90                   | 0.55, 1.45              | 0.6537  |
| **Duration from index diagnosis to advanced therapy initiation (months)** | 1.00                   | 0.99, 1.01              | 0.7598  |
| **QCI (ref = 0)**              |                        |                         |         |
| 1                              | 0.90                   | 0.68, 1.21              | 0.4911  |
| 2                              | 1.10                   | 0.84, 1.44              | 0.4843  |
| 3+                             | 1.22                   | 0.89, 1.68              | 0.2247  |
| **Other baseline conditions**  |                        |                         |         |
| Anemia (ref = no)              | 1.05                   | 0.89, 1.24              | 0.5703  |
| Dyslipidemia (ref = no)        | 1.11                   | 0.89, 1.39              | 0.3499  |
| Fibromyalgia (ref = no)        | 0.75                   | 0.27, 2.08              | 0.5804  |
| Hypertension (ref = no)        | 1.40                   | 1.13, 1.73              | 0.0022  |
| Mental illness/substance use disorder (ref = no) | 1.64                   | 1.38, 1.94              | <0.0001 |
| Osteoporosis (ref = no)        | 1.15                   | 0.78, 1.70              | 0.4806  |
| Infections (ref = no)          | 1.18                   | 0.99, 1.40              | 0.0649  |
| Nicotine dependence (ref = no) | 1.05                   | 0.86, 1.27              | 0.6412  |

Model adjusted for baseline pain conditions, age, gender, geographic region, plan type, Medicare advantage coverage, duration of index diagnosis to advanced therapies initiation, QCI, and other baseline conditions.

**Definitions:**
- **CDHP**: Consumer Driven Health Products
- **GEE**: Generalized estimating equations
- **HMO**: Health Maintenance Organization
- **PPO**: Provider Preferred Organization
- **PDC**: Proportion of days covered
- **QCI**: Quan-Charlson Comorbidity Index
- **UC**: Ulcerative colitis
increasingly rely on escalating pharmacotherapies, particularly advanced therapies.

To our knowledge, this is the first study reporting claims-based real-world data on pain medication use by patients with CD or UC on pain medication use before and after the initiation of advanced therapies. The current data highlight the prevalence of pain medication use in newly diagnosed patients with CD or UC.

This study has some limitations. It was not possible at all instances to know the circumstances for which patients were using pain medications (e.g., flaring disease, abdominal pain in the absence of active condition). Although we assessed pain medication use among patients with IBD, we cannot ascertain if the pain medication was prescribed for IBD specifically. Thus, it was not possible to stratify patients according to disease activity or severity. Although we assessed pain medication use among patients with IBD, over-the-counter pain medication use was not assessed. We cannot ascertain if the pain medication was prescribed for IBD specifically. The study population was limited to US patients who were insured (Anthem’s commercial or Medicare Advantage), which could impact the applicability of the results to other populations (traditional Medicare, Medicaid, uninsured populations, or non-US patients). There may be errors in the diagnosis of disease as coded on claims recorded in the databases. We did not include over-the-counter use of pain medication and had the short follow-up period of 12 months after the initiation of advanced therapies which does not address long-term trends in disease course and pain treatment therapies.

Conclusions
In summary, the findings reported here suggest that use of pain medications such as NSAIDs, glucocorticoids, opioids, and neuromodulators is common among patients with CD or UC. Additionally, the results highlight that those patients with CD or UC continued to receive pain medications even after initiating advanced therapies. These findings are clinically relevant because they suggest the complexity of IBD pain management. These data expand the literature on pain medication utilization for IBD abdominal pain, especially the role of advanced therapies. Future research is needed to develop better treatment plans for abdominal pain in IBD.

Abbreviations
S-ASA: S-Aminosalicylic acids; CD: Crohn’s disease; CFR: Code of Federal Regulations; CI: Confidence interval; CM: Clinical modification; EE: Exponentiated estimate; FDA: Food and Drug Administration; HIPAA: Health Insurance Portability and Accountability Act; HIROD: HealthCore Integrated Research Database; ICD: International Classification of Diseases; IBD: Inflammatory bowel disease; IRB: Institutional Review Board; ISPOR: International Society for Pharmacoeconomics and Outcomes Research; JAKI: Janus kinase inhibitors; NSAID: Nonsteroidal anti-inflammatory drugs; PDC: Proportion of days covered; QoL: Quality of life; TNF: Tumor necrosis factor inhibitors; UC: Ulcerative colitis; US: United States.

Acknowledgements
Priyanka Bannikoppa, an employee of Eli Lilly Services India Pvt. Ltd. provided writing support. Era Seth and Maanasa Surampally, the employees of Eli Lilly Services India Pvt. Ltd., provided support in addressing peer review comments from the journal with contributions from the authors.

Author contributions
TGH and KI contributed to conception, design, and interpretation of data; TH also contributed to drafting the manuscript. ANN, KG, MS, and HT contributed to design and interpretation of the data; HT also contributed to acquisition of the data along with CN, JLS and CN involved in the analysis of the data. All the authors were involved in the interpretation of the data and critical revision for the intellectual content. All authors read and approved the final manuscript.

Funding
The study was funded by Eli Lilly and Company.

Availability of data and materials
The HealthCore database is a proprietary health claims database and is not accessible to the public. HealthCore researchers were provided access pursuant to HIPAA. Further information concerning access to the HealthCore database may be provided upon request.

Declarations
Ethics approval and consent to participate
The study was conducted under the research provisions of Privacy Rule 45 CFR 164.514(E). The study used data that were previously collected and did not impose any form of intervention; the data were de-identified to protect subject privacy. Therefore, a formal consent was not required. This study was conducted in accordance with legal and regulatory requirements, as well as with scientific purpose, value and rigor, and follow Good Practices for Outcomes Research issued by ISPOR. The HealthCore database is a proprietary health claims database and is not accessible to the public. HealthCore researchers were provided access pursuant to HIPAA. Further information concerning access to the HealthCore database may be provided upon request by contacting the corresponding author.

Consent for publication
Not applicable.

Competing interests
C.N., J.L.S., and H.T. are employees of HealthCore, Inc., who received funding from Eli Lilly and Company to conduct this study. T.G.H., A.N.N., M.S., and K.G. are employees of Eli Lilly and Company. K.I. is an employee of Anthem, Inc.

Author details
1 Eli Lilly and Company, 893 S. Delaware Street, Indianapolis, IN 46225, USA. 2 HealthCore, Inc., Wilmington, USA. 3 Anthem, Inc., Indianapolis, USA.

Received: 19 October 2021 Accepted: 15 November 2022
Published online: 19 November 2022

References
1. Sairenji T, Collins KL, Evans DV. An update on inflammatory bowel disease. Prim Care. 2017;44(4):673–92.
2. Alatab S, Sepanlou SG, Ikuta K, Vahedi H, Bisignano C, Safiri S, Sadeghi A, Nixon MR, Abdoli A, Abolhassani H, et al. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2020;5(1):17–30.
3. Loftus EV Jr. Update on the incidence and prevalence of inflammatory bowel disease in the United States. Gastroenterol Hepatol. 2016;12(11):704–7.
4. Dougan M, Wang Y, Rubio-Tapia A, Lim JK. AGA clinical practice update on diagnosis and management of Immune Checkpoint Inhibitor (ICI)- induced colitis and hepatitis: expert review. Gastroenterology. 2020. https://doi.org/10.1053/j.gastro.2020.08.063.

5. Bielefeldt K, Davis B, Binon DG. Pain and inflammatory bowel disease. Inflamm Bowel Dis. 2009;15(5):778–88.

6. Docherty MJ, Jones RCW 3rd, Wallace MS. Managing pain in inflammatory bowel disease. Gastroenterology. 2011;7(9):592–601.

7. Srinath AI, Walter C, Newara MC, Szigethy EM. Pain management in patients with inflammatory bowel disease: insights for the clinician. Therap Adv Gastroenterol. 2012;5(5):339–57.

8. Wagtman MJ, Verspaget HW, Lamers CBM, van Hoogezand RA. Crohn’s disease in the elderly: a comparison with young adults. J Clin Gastroenterol. 1998;27(2):129–33.

9. Schirbel A, Reichert A, Roll S, Baumgart DC, Büning C, Wittig B, Wiedenmann B, Dignass A, Sturm A. Impact of pain on health-related quality of life in patients with inflammatory bowel disease. World J Gastroenterol. 2010;16(25):3168–77.

10. Zielinska A, Salaga M, Wolderzyck-M, Fichna J. Focus on current and future management possibilities in inflammatory bowel disease-related chronic pain. Int J Colorectal Dis. 2019;34(1):217–27.

11. Veloso FT, Carvalho J, Magro F. Immune-related systemic manifestations of inflammatory bowel disease. A prospective study of 792 patients. J Clin Gastroenterol. 1996;23(1):29–34.

12. Isaacs KL. How prevalent are extraintestinal manifestations at the initial diagnosis of IBD? Inflamm Bowel Dis. 2008;14(2):S198-199.

13. Isaac KL. How prevalent are extraintestinal manifestations at the initial diagnosis of IBD? Inflamm Bowel Dis. 2008;14(2):S198-199.

14. Long MD, Kappelman MD, Martin CF, Chen W, Anton K, Sandler RS. Role of nonsteroidal anti-inflammatory drugs in exacerbations of inflammatory bowel disease. J Clin Gastroenterol. 2016;50(2):152–6.

15. Targownik LE, Nugent Z, Singh H, Bugden S, Bernstein CN. The prevalence and predictors of opioid use in inflammatory bowel disease: a population-based analysis. Am J Gastroenterol. 2014;109(10):1613–20.

16. Moreno N, Ripollés T, Paredes JM, Ortiz I, Martínez MJ, López A, Delgado F, Moreno-Osset E. Usefulness of abdominal ultrasonography in the analysis of endoscopic activity in patients with Crohn’s disease: changes following treatment with immunomodulators and/or anti-TNF agents. J Crohns Colitis. 2014;8(9):1079–87.

17. Paredes JM, Ripollés T, Cortés X, Martínez MJ, Barrachina M, Gómez F, Moreno-Osset E. Abdominal sonographic changes after antibody to tumor necrosis factor (anti-TNF) alpha therapy in Crohn’s disease. Dig Dis Sci. 2010;55(2):404–10.

18. Cañete JD, Pablos JL. Biologic therapy in rheumatoid arthritis. Curr Top Med Chem. 2013;13(6):752–9.

19. D’Haens G. Risks and benefits of biologic therapy for inflammatory bowel diseases. Gut. 2007;56(5):725.

20. Silva RPL, Baima JP, Biscoli GC, Farinelli E, Sibia CF, Barros JR, Biondi RB, Renosto FL, Hosseini RS, Saisaki LY. Chinese Anti-TNF therapy improves the quality of life in patients with ulcerative colitis. J Crohns Colitis. 2017;11(suppl_1):S498–9.

21. Rubin DT, Ananthakrishnan AN, Siegel CA, Sauer BG, Long MD. ACG clinical guideline: ulcerative colitis in adults. Am Coll Gastroenterol (ACG). 2019;114(3):384–413.

22. Romanelli RJ, Shah SN, Ikeda L, Lynch B, Craig TL, Cappellari JC, Jukes T, Ishiaka D. Patient characteristics and healthcare utilization of a chronic pain population within an integrated healthcare system. Am J Manag Care. 2017;23(2):e50–6.

23. Peterson AM, Nau DP, Cramer JA, Benner J, Gwadry-Sridhar F, Nichol M. A checklist for medication compliance and persistence studies using retrospective databases. Value Health. 2007;10(1):3–12.

24. Siegel CA, Yang F, Eslava S, Cai Z. Treatment pathways leading to biologic therapies for ulcerative colitis and Crohn’s disease in the United States. Clin Transl Gastroenterol. 2020;11(2):e00128.

25. Dubois-Camacho K, Ottum PA, Franco-Muñoz D, De la Fuente M, Torres-Riquelme A, Díaz-Jiménez D, Olivares-Morales M, Astudillo G, Quera R, Herrnso MA. Glucocorticosteroid therapy in inflammatory bowel disease: from clinical practice to molecular biology. World J Gastroenterol. 2017;23(36):6628–38.

26. Makharia GK. Understanding and treating abdominal pain and spasms in organic gastrointestinal diseases: inflammatory bowel disease and biliary diseases. J Clin Gastroenterol. 2011;45(Suppl):S89-93.

27. Stott M, Devlin S, Kaplan GG, Panaccione R, Andrews CN. Cannabis use provides symptom relief in patients with inflammatory bowel disease but is associated with worse disease prognosis in patients with Crohn’s disease. Inflamm Bowel Dis. 2014;20(3):472–80.

28. Yu H, Maclsaac D, Wong J, Sellers ZM, Wren AA, Benson R, Kin C, Park KT. Market share and costs of biologic therapies for inflammatory bowel disease in the USA. Aliment Pharmacol Ther. 2018;47(3):364–70.

29. Kirchgesner J, Lemaitre M, Rudnicki A, Racine A, Zurek M, Carbonnel F, Dray-Spira R. Therapeutic management of inflammatory bowel disease in real-life practice in the current era of anti-TNF agents: analysis of the French administrative health databases 2009–2014. Aliment Pharmacol Ther. 2017;45(1):37–49.

30. Rubin DT, Mody R, Davis RL, Wang CC. Real-world assessment of therapy changes, suboptimal treatment and associated costs in patients with ulcerative colitis or Crohn’s disease. Aliment Pharmacol Ther. 2014;39(10):1143–55.

31. Kaplan MA, Koretz BI. Narcotic dependence in inflammatory bowel disease. J Clin Gastroenterol. 1988;10(3):275–8.

32. Cross RK, Wilson KT, Binon DG. Narcotic use in patients with Crohn’s disease. Am J Gastroenterol. 2005;100(10):2225–9.

33. Edwards JT, Radford-Smith GJ, Florin TH. Chronic narcotic use in inflammatory bowel disease patients: prevalence and clinical characteristics. J Gastroenterol Hepatol. 2001;16(11):1235–8.

34. Khan N, Abbas A, Williamson A, Balant L. Prevalence of corticosteroids use and disease course after initial steroid exposure in ulcerative colitis. Dig Dis Sci. 2013;58(10):2963–9.

35. Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, van Hoogstaden Hi, Chen AC, Zheng H, Danese S, et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology. 2010;138(8):1509-1521.e1505.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.